

Table S1. Antimicrobial susceptibilities of extended β -lactam-resistant *E. coli* (n=120) and *K. pneumoniae* (n=108) isolates to five antimicrobial agents

Species	Antimicrobial agent	Inoculum size	Cumulative % of isolates with indicated MICs (mg/L)															MIC (mg/L) ^a		S (%) ^b
			≤0.03	0.06	0.125	0.25	0.5	1	2	4	8	16	32	64	128	256	≥512	MIC ₅₀	MIC ₉₀	
<i>E. coli</i>	Ceftazidime	Standard						4.2	13.3	17.5	32.5	46.7	70.0	81.7	94.2	96.7	100	32	128	17.5
		High						0.8	3.3	8.3	14.2	24.2	34.2	44.2	55.8	74.2	100	≥512	≥512	8.3
	Aztreonam	Standard					0.8		4.2	7.5	19.2	33.3	48.3	71.7	87.5	100 ^c		64	≥256	7.5
		High								0.8		4.2	10.0	15.8	35.0	100 ^c		≥256	≥256	0.8
	Ceftazidime-avibactam	Standard	0.8		6.7	53.3	88.3	98.3		99.2	100							0.25	1	100
		High			0.8	25.8	70.8	89.2	90.0		93.3	97.5	99.2				100	0.5	2	93.3
	Aztreonam-avibactam	Standard	0.8	22.5	78.3	95.8	96.7	97.5	98.3	99.2		100						0.125	0.25	N/A
		High		10.8	63.3	84.2	86.7	88.3		89.2	90.0	91.7	92.5	95.0	96.7	97.5	100	0.125	8	N/A
	Meropenem	Standard	85.0	94.2	96.7	97.5	99.2			100								0.03	0.06	99.2
		High	20.8	74.2	85.0	86.7	93.3			97.5	99.2		100					0.06	0.5	93.3
<i>K. pneumoniae</i>	Ceftazidime	Standard								6.5	9.3	13.9	19.4	25.9	32.4	51.9	100	256	≥512	6.5
		High								0.9			2.8	3.7	5.6	9.3	100	≥512	≥512	0.9
	Aztreonam	Standard					2.8		3.7	4.6	6.5	9.3	15.7	24.1	37.0	100 ^c		≥256	≥256	4.6
		High						0.9								100 ^c		≥256	≥256	0.9

Ceftazidime-	Standard			0.9	9.3	37.0	69.4	89.8	97.2	98.1	99.1			100			1	4	98.1
avibactam	High				4.6	22.2	38.0	62.0	80.6	90.7	94.4	96.3	98.1	100			2	8	90.7
Aztreonam-	Standard	0.9	15.7	54.6	79.6	87.0	91.7	96.3	98.1		99.1	100					0.125	1	N/A
avibactam	High		4.6	20.4	34.3	42.6	44.4	48.1	52.8	79.6	82.4	85.2	86.1	88.0	93.5	100	4	256	N/A
Meropenem	Standard	38.0	73.1	81.5	89.8	92.6		93.5	94.4	96.3		97.2	100				0.06	0.5	92.6
	High	3.7	9.3	18.5	23.1	49.1	63.9	75.9	79.6		88.0	90.7	100				1	32	63.9

^a 50% and 90%, MICs at which 50% and 90% of isolates are inhibited, respectively.

^b The CLSI susceptibility breakpoint was used; ceftazidime, ≤ 4 mg/L; aztreonam, ≤ 4 mg/L; ceftazidime-avibactam, $\leq 8/4$ mg/L; meropenem, ≤ 1 mg/L; no breakpoint criteria have been defined for aztreonam-avibactam.

^c MIC is \geq the indicated value.

MIC, minimum inhibitory concentration; N/A, not available; S, susceptible.